Evidence mapPaperPMID 32409985Full record

ArticlePharmaceutical research2020

Novel application of synchrotron x-ray computed tomography for ex-vivo imaging of subcutaneously injected polymeric microsphere suspension formulations.

Claire Patterson, Dean Murphy, Sarah Irvine, Leigh Connor, Zahra Rattray

Open access · hybridAbstract read
In one paragraph

Article in Pharmaceutical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Claire PattersonEarly Pharmaceutical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, UK.
Dean MurphyPharmaceutical Technology and Development, R&D, AstraZeneca, Macclesfield, UK.
Sarah IrvineDiamond Light Source, Harwell science and innovation campus, Oxfordshire, UK.
Leigh ConnorDiamond Light Source, Harwell science and innovation campus, Oxfordshire, UK.
Zahra RattrayEarly Pharmaceutical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, UK. zahra.rattray@strath.ac.uk.ORCID http://orcid.org/0000-0002-8371-8549
AstraZeneca (United Kingdom) · GBDiamond Light Source · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSubcutaneously or intramuscularly administered biodegradable microsphere formulations have been successfully exploited in the management of chronic conditions for over two decades, yet mechanistic understanding of the impact of formulation attributes on in vivo absorption rate from such systems is still in its infancy.

methodsSuspension formulation physicochemical attributes may impact particulate deposition in subcutaneous (s.c.) tissue. Hence, the utility of synchrotron X-ray micro-computed tomography (μCT) for assessment of spatial distribution of suspension formulation components (PLG microspheres and vehicle) was evaluated in a porcine s.c. tissue model. Optical imaging of dyed vehicle and subsequent microscopic assessment of microsphere deposition was performed in parallel to compare the two approaches.

resultsOur findings demonstrate that synchrotron μCT can be applied to the assessment of microsphere and vehicle distribution in s.c. tissue, and that microspheres can also be visualised in the absence of contrast agent using this approach. The technique was deemed superior to optical imaging of macrotomy for the characterisation of microsphere deposition owing to its non-invasive nature and relatively rapid data acquisition time.

conclusionsThe method outlined in this study provides a proof of concept feasibility for μCT application to determining the vehicle and suspended PLG microspheres fate following s.c. injection. A potential application for our findings is understanding the impact of injection, device and formulation variables on initial and temporal depot geometry in pre-clinical or ex-vivo models that can inform product design. Graphical abstract.

Indexed as

MicrospheresAnimalsBiocompatible MaterialsContrast MediaDrug CompoundingImaging, Three-DimensionalInjections, SubcutaneousPolylactic Acid-Polyglycolic Acid CopolymerRadiographic Image EnhancementSuspensionsSwineSynchrotronsTissue ScaffoldsTomography, X-Ray ComputedBiocompatible MaterialsContrast MediaPolylactic Acid-Polyglycolic Acid CopolymerSuspensionsdepotimagingmicrospheresubcutaneous injectionvehicleX-ray computed tomography

Identifiers

PMID32409985
PMCPMC7225200
OpenAlexW3024387107

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.